SPYRE THERAPEUTICS, INC. (SYRE)

Director Albers Jeffrey W. 🟡 adjusted position in 23.0K shares (1 derivative) of Spyre Therapeutics, Inc. (SYRE) at $104.68 ($2.5M) Transaction Date: Aug 07, 2026 | Filing ID: 000102